GlassScriptPhysician profile
Kimberly A Smallwood
NPI 1538670690
$3,462.96
in general payments reported to CMS, 2019-2025
29 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $656 · 2023: $693 · 2024: $973 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $465.75 | 2022-2025 | |
| Novo Nordisk INC | $464.59 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $435.80 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $414.93 | 2022-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $348.24 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $165.04 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.09 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $132.82 | 2022-2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $109.80 | 2023-2025 | Rexulti |
| Amgen INC. | $96.16 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Exact Sciences Corporation | $81.47 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $80.50 | 2022 | |
| Abbvie INC. | $66.04 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $49.67 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $40.79 | 2025 | Jornay Pm |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.24 | 2023-2024 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $36.87 | 2022 | |
| Abbott Laboratories | $34.99 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $31.31 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $30.99 | 2024 | Onzetra Xsail, Contrave |
| Janssen Pharmaceuticals, INC | $30.96 | 2023 | Xarelto |
| Organon LLC | $25.82 | 2025 | Nexplanon |
| Corium, LLC | $25.34 | 2025 | Azstarys |
| Biogen, INC. | $23.44 | 2024 | Skyclarys |
| Mylan Specialty L.P. | $21.58 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $20.02 | 2022 | |
| Mayne Pharma Commercial LLC | $17.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.72 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $14.14 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Smallwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.